Morgan Stanley
BBNX

Morgan Stanley’s Beta Bionics BBNX Stock Holding History

Morgan Stanley’s Portfolio BBNX Stock Details BBNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66.9M Buy
4,266,822
+39,188
+0.9% +$466K ﹤0.01% 1947
2026
Q1 		$42.4M Buy
4,227,634
+768,181
+22% +$11.4M ﹤0.01% 2278
2025
Q4 		$105M Sell
3,459,453
-302,130
-8% -$8.07M 0.01% 1408
2025
Q3 		$74.7M Buy
3,761,583
+812,218
+28% +$14.3M ﹤0.01% 1671
2025
Q2 		$42.9M Buy
2,949,365
+1,547,712
+110% +$21.9M ﹤0.01% 2065
2025
Q1 		$17.2M Buy
+1,401,653
New +$26.1M ﹤0.01% 2850

Other funds holding BBNX

EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
SCV
Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Morgan Stanley's BBNX Position: Q2 2026 in Review

Morgan Stanley increased its Beta Bionics (BBNX) stake by 0.93% in Q2 2026, buying an estimated $466K and bringing the position to 4,266,822 shares worth $66.9M. The position accounts for ﹤0.01% of the portfolio, ranked #1947.

Morgan Stanley first reported a position in BBNX in Q1 2025 and has held it in 6 quarters since. The position peaked at $105M in Q4 2025. 134 funds tracked by Wall St. Rank hold BBNX as of Q2 2026.

  • Morgan Stanley held 4,266,822 shares of Beta Bionics worth $66.9M as of Q2 2026.
  • Morgan Stanley bought 39,188 Beta Bionics shares in Q2 2026, an estimated $466K.
  • Beta Bionics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #1947 holding.
  • Morgan Stanley first reported a position in Beta Bionics in Q1 2025 and has held it in 6 quarters since.
  • Morgan Stanley's Beta Bionics position peaked at $105M in Q4 2025.
  • 134 funds tracked by Wall St. Rank held Beta Bionics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.